Mirum Insider Moves Signal Bullish Outlook Amid FDA Fast‑Track and New Therapeutics
Mirum insider moves reveal strategic confidence: Saira buys low, sells high while keeping long‑term stake, amid fast‑track FXR drug progress and promising NASH results.
4 minutes to read